CranioView

Cover Block

Name	CranioView
Tagline	Wearable, noninvasive device using ocular ultrasound and machine learning to monitor intracranial pressure.
Headquarters	San Francisco, CA, United States
Founded	2020
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

• Website: https://www.cranioview.com
• LinkedIn: https://www.linkedin.com/company/cranioview-inc

Executive Summary

CranioView is developing a wearable, noninvasive device that uses ocular ultrasound and machine learning to continuously monitor intracranial pressure (ICP), a technology that, if proven, could address a critical unmet need in neurocritical care [cranioview.com]. Founded in 2020, the company is an early-stage healthtech venture that has disclosed minimal public information, operating with an estimated team of one to ten employees [Prospeo]. Its core proposition is a hardware-plus-software solution that aims to replace invasive, high-risk monitoring procedures with a simpler, continuous alternative for patients with acute neurological injuries.

The founding team is led by Gil Herrnstadt, a CEO with a background in medical robotics and translational research [LinkedIn]. A co-founder is identified as a physician with experience in healthcare consulting [cranioview.com]. The company has acknowledged receiving support from UCLA and participation in the Magnify Incubator at CNSI, but specific funding amounts, lead investors, and a detailed capitalization table are not publicly available [F6S].

For investors, the next 12 to 18 months will be defined by the company's ability to transition from concept to clinical validation. Key milestones include securing regulatory clearances, initiating pilot studies with hospital partners, and providing the first public data on the device's accuracy and clinical utility.

Data Accuracy: YELLOW -- Core product claims are confirmed from the company website; team and funding details are partially corroborated by third-party databases but lack independent verification.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

How the Company Got Here

CranioView, Inc. was founded in 2020, a timing that places its genesis within a period of heightened investor and clinical interest in remote patient monitoring and non-invasive diagnostics [F6S]. The company maintains its headquarters in San Francisco, California [LinkedIn]. The founding narrative centers on a team of physicians and engineers dedicated to advancing neurocritical care [cranioview.com].

Its participation in the Magnify Incubator at the California NanoSystems Institute (CNSI) at UCLA represents a significant early-stage milestone, providing access to laboratory space, mentorship, and an institutional affiliation [cranioview.com]. The company has secured seed-stage capital, with investor interest noted from UCLA among others, though the specific round details remain undisclosed [F6S].

Operational scale is modest, with public sources estimating the team size at between one and ten employees [Prospeo]. The company's public footprint is minimal, with no press releases, regulatory announcements, or detailed funding disclosures available from named-publisher sources.

Data Accuracy: YELLOW -- Founding year and incubator participation confirmed by company website; headquarters and team size corroborated by LinkedIn and Prospeo. Funding details and specific milestones lack independent public verification.

Product and Technology

CranioView’s core proposition is a hardware-software system designed to replace an invasive clinical procedure with a wearable monitor. The company’s flagship product is a wearable, noninvasive device that uses ocular ultrasound and machine learning to continuously monitor intracranial pressure (ICP) [cranioview.com]. The intended use case is patients with neurological injuries in neurocritical care settings, where continuous ICP monitoring currently requires drilling a small hole in the skull to place a sensor [cranioview.com].

The technical approach centers on transcranial Doppler ultrasonography (TCD-US). The device images blood flow in the ophthalmic artery, central retinal artery, and posterior ciliary arteries, using these signals as a proxy for pressure inside the skull [cranioview.com]. A machine learning component is then applied to interpret the ultrasound data and produce an accurate ICP reading. The company describes the system as self-calibrating [cranioview.com].

Public materials frame the product strictly as a development-stage medical device. There are no disclosed specifications regarding battery life, form factor, or connectivity. The status of regulatory submissions, clinical validation, or any pilot deployments with hospital partners is not publicly available.

Data Accuracy: YELLOW -- Product claims are consistent across the company website and several third-party databases, but technical details and development status are not corroborated by independent clinical or engineering publications.

Where the Demand Sits

The market for noninvasive intracranial pressure monitoring is driven by a clinical imperative to reduce the mortality and morbidity associated with traumatic brain injuries.

The broader market for neuromonitoring devices was valued at $2.1 billion globally in 2021 and is projected to reach $3.4 billion by 2028 [Grand View Research, 2022]. The serviceable obtainable market for a device like CranioView's would be a narrower segment focused on acute neurocritical care, where an estimated 1.7 million Americans sustain a TBI annually, and over 50,000 die from these injuries [CDC].

Key demand drivers are clinical and economic. The current gold standard for ICP monitoring requires drilling a burr hole through the skull to place a catheter or sensor, a procedure carrying risks of hemorrhage, infection, and cerebrospinal fluid leak [Journal of Neurosurgery]. A reliable noninvasive alternative could expand monitoring to a wider patient population. Furthermore, continuous monitoring could enable earlier intervention to prevent secondary brain injury, potentially improving outcomes and reducing length of stay in intensive care units.

Regulatory pathways and reimbursement structures are critical macro forces. Any novel device would require FDA clearance, likely through the 510(k) or De Novo pathways [FDA]. Success also hinges on securing favorable reimbursement codes from the Centers for Medicare & Medicaid Services and private payers.

Metric	Value
Global Neuromonitoring Devices Market (Analogous) 2021	$2.1B
Projected Market 2028	$3.4B

Data Accuracy: YELLOW -- Market sizing is based on an analogous sector report from a named publisher; specific TAM for noninvasive ICP monitoring is not confirmed.

Competitive Landscape

CranioView enters a clinical monitoring segment defined by a choice between an invasive gold standard and a collection of non-invasive technologies.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
CranioView	Wearable, non-invasive ICP monitor using ocular ultrasound & ML for neurocritical care.	Seed; investor UCLA; part of Magnify Incubator at CNSI (UCLA).	Self-calibrating device based on transcranial Doppler ultrasonography (TCD-US) imaging specific ocular arteries.	[cranioview.com]

The competitive map for intracranial pressure monitoring is stratified by clinical risk tolerance and technological approach. The incumbent standard is the invasive intraventricular catheter, supplied by firms like Integra LifeSciences and Medtronic. The non-invasive segment is populated by challengers employing techniques including tympanic membrane displacement, optic nerve sheath diameter ultrasound, and transcranial Doppler. CranioSense operates in this same non-invasive category.

CranioView's claimed edge rests on its specific technical pathway, transcranial Doppler ultrasonography focused on the ophthalmic artery and its branches, combined with a machine learning layer. The company's physician-engineer founding team provides a translational research background. This edge is contingent on unproven clinical accuracy and has not yet been fortified by peer-reviewed data, regulatory clearance, or intellectual property visible in public records.

Data Accuracy: YELLOW -- Subject's positioning is confirmed by company sources; one competitor is named but with minimal corroborating detail. Broader market context is established from standard clinical practice.

Opportunity

If CranioView successfully commercializes its noninvasive intracranial pressure monitor, the prize is a position in a high-stakes segment of neurocritical care monitoring.

The headline opportunity is to become the standard-of-care, noninvasive monitoring device for traumatic brain injury (TBI) and stroke patients in intensive care units. The company is targeting a clear, unmet clinical need: continuous ICP monitoring is vital for managing severe neurological injuries, but the current gold standard requires drilling a hole in the skull [cranioview.com].

Scenario	What happens	Catalyst	Why it's plausible
Standard of Care in Neuro-ICUs	The device becomes a mandatory piece of equipment for monitoring severe TBI and stroke patients.	Successful FDA clearance and publication of a pivotal clinical trial demonstrating non-inferiority to invasive ICP monitoring.	The clinical demand for a safer, continuous monitor is well-established.
Expansion to Neurological Wards & ERs	Monitoring expands beyond the ICU to lower-acuity hospital wards and emergency rooms.	A follow-on, simplified version of the device designed for easier application by non-specialist staff.	The core value proposition is compelling in settings where invasive monitoring is impractical.
Long-term Monitoring for Chronic Conditions	The wearable form factor enables outpatient monitoring for conditions like idiopathic intracranial hypertension.	Partnerships with neurology clinics and payer reimbursement for at-home monitoring codes.	The company describes its product as a "wearable" device, implying a design intended for extended use [cranioview.com].

Compounding for CranioView would manifest as a clinical data moat. Each device deployment would generate unique, continuous ICP waveforms paired with patient outcomes. This dataset would be proprietary and critical for refining the machine learning algorithms.

Data Accuracy: YELLOW -- The core product description and target market are confirmed by the company's website. Market size and growth projections are cited from a named industry report.

The Analyst's Last Word

Verdict: WATCH, The company is in a high-risk, high-potential category where technical execution is the primary determinant of value. Conviction: Moderate Time horizon: 12 to 18 months

Data Accuracy: YELLOW -- Analyst notes are based on the absence of public clinical data and the early-stage nature of the venture.

Sources

1. [cranioview.com] About | https://www.cranioview.com/about
2. [LinkedIn] CranioView, Inc. | https://www.linkedin.com/company/cranioview-inc
3. [Prospeo] CranioView Email Format & Contact Info | https://prospeo.io/c/cranioview-email-format
4. [F6S] CranioView | F6S | https://www.f6s.com/company/cranioview
5. [Grand View Research, 2022] Global Neuromonitoring Devices Market Size Report | https://www.grandviewresearch.com/industry-analysis/neuromonitoring-devices-market
6. [CDC] Traumatic Brain Injury & Concussion | https://www.cdc.gov/traumaticbraininjury/index.html
7. [Journal of Neurosurgery] Complications of invasive intracranial pressure monitoring | https://thejns.org/view/journals/j-neurosurg/aop/article-10.3171-2023.3.JNS23230/article-10.3171-2023.3.JNS23230.xml
8. [FDA] Medical Device Development | https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/medical-device-development
9. [Grand View Research, 2024] Intracranial Pressure Monitoring Devices Market Size Report | https://www.grandviewresearch.com/industry-analysis/intracranial-pressure-monitoring-devices-market